Cancer Screening Recommendations for Individuals with Li-Fraumeni Syndrome.

doi:10.1158/1078-0432.CCR-17-0408

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Cancer Screening Recommendations for Individuals with Li-Fraumeni Syndrome.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Jun 2017

Kratz Christian P, Achatz Maria Isabel, Brugières Laurence, Frebourg Thierry, Garber Judy E, Greer Mary-Louise C, Hansford Jordan R, Janeway Katherine A, Kohlmann Wendy K, McGee Rose, Mullighan Charles G, Onel Kenan, Pajtler Kristian W, Pfister Stefan M, Savage Sharon A, Schiffman Joshua D, Schneider Katherine A, Strong Louise C, Evans D Gareth R, Wasserman Jonathan D, Villani Anita, Malkin David

Abstract excerpt

Li-Fraumeni syndrome (LFS) is an autosomal dominantly inherited condition caused by germline mutations of the TP53 tumor suppressor gene encoding p53, a transcription factor triggered as a protective cellular mechanism against different stressors. Loss of p53 function renders affected individuals highly susceptible to a broad range of solid and hematologic cancers. It has recently become evident that children and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related Molecular Pathways

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Child

Share to Early Detection of Cancer

Share to Epigenetics and DNA Methylation

Share to Genetic Predisposition to Disease

Share to Germ-Line Mutation

Share to Li-Fraumeni Syndrome

Share to Tumor Suppressor Protein p53

Source

Open in PubMed

Identifiers

PMID: 28572266
DOI: 10.1158/1078-0432.CCR-17-0408

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cancer Screening Recommendations for Individuals with Li-Fraumeni Syndrome.PMID 28572266Read ↗

Update on Cancer Screening Recommendations for Individuals with Li–Fraumeni SyndromeSemantic proximity Read ↗

Inherited TP53 Mutations and the Li-Fraumeni Syndrome.Semantic proximity Read ↗

Germline TP53 mutations and the changing landscape of Li-Fraumeni syndrome.Semantic proximity Read ↗

Current insights and future directions of Li-Fraumeni syndromeSemantic proximity Read ↗

Li-Fraumeni syndrome: a paradigm for the understanding of hereditary cancer predisposition.Semantic proximity Read ↗

New Paradigms in the Clinical Management of Li-Fraumeni Syndrome.Semantic proximity Read ↗

Medical guidelines for Li-Fraumeni syndrome 2019, version 1.1.Semantic proximity Read ↗

Li–Fraumeni Syndrome: Mutation of TP53 Is a Biomarker of Hereditary Predisposition to Tumor: New Insights and Advances in the TreatmentSemantic proximity Read ↗

Li-Fraumeni SyndromeSemantic proximity Read ↗

Personalized screening strategies for TP53 R337H carriers: a retrospective cohort study of tumor spectrum in Li-Fraumeni syndrome adult carriersSemantic proximity Read ↗

The benefit and burden of cancer screening in Li-Fraumeni syndrome: a case report.Semantic proximity Read ↗

The Li-Fraumeni syndrome.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.